A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit <a rel="external noopener" href="https://www.jstage.jst.go.jp/article/bpb/35/6/35_by110119/_pdf">the original URL</a>. The file type is <code>application/pdf</code>.
<i title="Pharmaceutical Society of Japan">
<a target="_blank" rel="noopener" href="https://fatcat.wiki/container/7dhzdojg5jdw5it56w2wbapkgi" style="color: black;">Biological and Pharmaceutical Bulletin</a>
The recent emergence of multidrug-resistant pathogens and/or pharmacokinetics-pharmacodynamics considerations may result in off-label use of a certain class of antibacterials, including tigecycline. This study was performed to clarify the safety profile of tigecycline in the user-derived manner and to compare it with the prescribing information provided by the manufacturer. Numerous spontaneous adverse event reports (AERs) submitted to the U.S. Food and Drug Administration (FDA) were analyzed<span class="external-identifiers"> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1248/bpb.35.967">doi:10.1248/bpb.35.967</a> <a target="_blank" rel="external noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/22687540">pmid:22687540</a> <a target="_blank" rel="external noopener" href="https://fatcat.wiki/release/lkptxhq4kffr3numpenm3xudtq">fatcat:lkptxhq4kffr3numpenm3xudtq</a> </span>
more »... ter a revision of arbitrary drug names and the deletion of duplicated submissions. Standardized official pharmacovigilance tools were used for quantitative detection of signals, i.e., drug-associated adverse events, including the proportional reporting ratio, the reporting odds ratio, the information component given by a Bayesian confidence propagation neural network, and the empirical Bayes geometric mean. Based on 22017956 co-occurrences, i.e., drug-adverse event pairs, found in 1644220 AERs from 2004 to 2009, 248 adverse events were suggested as tigecycline-associated ones. Adverse events with a relatively high frequency included nausea, vomiting, pancreatitis, hepatic failure, hypoglycemia, and increase in levels of alanine aminotransferase, bilirubin, alkaline phosphatase, aspartate aminotransferase, and gamma-glutamyltransferase. It is noted that cholestasis, jaundice, an increase in International Normalized Ratio, and Stevens-Johnson syndrome were also, although they were infrequent. The adverse events suggested were in agreement with information provided by the manufacturer, suggesting that off-label use hardly results in unexpected adverse events, presumably due to usage with extreme caution.
<a target="_blank" rel="noopener" href="https://web.archive.org/web/20181101121339/https://www.jstage.jst.go.jp/article/bpb/35/6/35_by110119/_pdf" title="fulltext PDF download" data-goatcounter-click="serp-fulltext" data-goatcounter-title="serp-fulltext"> <button class="ui simple right pointing dropdown compact black labeled icon button serp-button"> <i class="icon ia-icon"></i> Web Archive [PDF] <div class="menu fulltext-thumbnail"> <img src="https://blobs.fatcat.wiki/thumbnail/pdf/79/ee/79ee8037577f8da9a811b7ddde1e0aac0b5ebdb7.180px.jpg" alt="fulltext thumbnail" loading="lazy"> </div> </button> </a> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1248/bpb.35.967"> <button class="ui left aligned compact blue labeled icon button serp-button"> <i class="external alternate icon"></i> Publisher / doi.org </button> </a>